| 摘要 |
Disclosed is a pharmaceutical composition for treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists. The pharmaceutical composition comprises a therapeutically effective amount of at least one compound selected from the group consisting of 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5- [4-(2-piperidin-1-yl-ethoxy)benzyl]naphthalen-2-oll and {4-[2- (2-azabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl}-[6-hyydroxy-2-(4- hydroxy-phenyl)benzo[b]thiophen-3-yl]methanone or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
|
